Sign In
Buy RCUS
$23.86
-0.610 (-2.49%)
At Close: Jun 03, 2026
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
12:55pm, Thursday, 04'th Jun 2026
Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for
Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
04:05pm, Tuesday, 26'th May 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patient
Arcus Biosciences, Inc. (RCUS) Q1 2026 Earnings Call Transcript
12:21am, Wednesday, 06'th May 2026
Arcus Biosciences, Inc. (RCUS) Q1 2026 Earnings Call Transcript
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue Estimates
07:10pm, Tuesday, 05'th May 2026
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $1.14 per share a year ago.
Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update
04:05pm, Tuesday, 05'th May 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:06am, Tuesday, 28'th Apr 2026
Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcus Biosciences Announces New Employment Inducement Grants
04:05pm, Friday, 24'th Apr 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
What's Going On With Arcus Biosciences Stock On Wednesday?
03:19pm, Wednesday, 22'nd Apr 2026
Cancer-focused biotech, Arcus Biosciences, Inc. (NYSE:RCUS) stock is trading higher on Wednesday after the company's stock closed lower on Tuesday following a lung cancer trial update.
Arcus Biosciences (RCUS) Moves 7.8% Higher: Will This Strength Last?
08:36am, Wednesday, 22'nd Apr 2026
Arcus Biosciences (RCUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price in
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates
04:05pm, Tuesday, 21'st Apr 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patient
Financial Analysis: Arcus Biosciences (NYSE:RCUS) vs. Immunovant (NASDAQ:IMVT)
04:14am, Saturday, 11'th Apr 2026
Arcus Biosciences (NYSE: RCUS - Get Free Report) and Immunovant (NASDAQ: IMVT - Get Free Report) are both mid-cap medical companies, but which is the superior investment? We will compare the two compa
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Thursday, 09'th Apr 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences (NYSE:RCUS) Trading Up 5.4% Following Analyst Upgrade
01:19am, Friday, 03'rd Apr 2026
Arcus Biosciences, Inc. (NYSE: RCUS - Get Free Report) shares were up 5.4% on Thursday after Wedbush raised their price target on the stock from $37.00 to $41.00. Wedbush currently has an outperform r
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up
07:05am, Wednesday, 01'st Apr 2026
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms.
